No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma

Summary: Despite recent advances, multiple myeloma remains essentially incurable for most patients, particularly those with high-risk cytogenetics and those whose disease relapses after BCMA-targeting therapies. A novel CD27 CAR_sIL15 NK cell targeting CD70 may offer new hope in this area of urgent, unmet medical need. See related article by Lin et al., p. XX .